Novo Nordisk’s CEO says compounded GLP-1 knockoffs sourced from overseas ingredients could endanger patients and undermine FDA oversight as legal battle escalates.

Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is seeking to recover damages.

FDA enforcement will focus on restricting GLP-1 APIs in mass-marketed, nonapproved compounded products to address unverifiable quality, safety, and efficacy under the FD&C Act. Appropriate compounding ...

The FDA has outlined numerous concerns about the sale and use of unapproved GLP-1 drugs for weight loss.  “FDA is aware that ...

Hims is breaching the U.S. patent on semaglutide, the active ingredient in Novo’s Wegovy obesity treatments, Novo argued ...

Semaglutide is the active ingredient in Ozempic and Wegovy. It’s a synthetic form of GLP-1, a hormone that regulates our ...

With online health and wellness company Hims & Hers opening a new front in the GLP-1 compounding showdown Thursday, the ...

As a youth activist in Colorado, I’ve spent years organizing around the issues that shape our generation’s lives — and across ...

If compounded and generic GLP-1 drugs work as well as brand-name versions, they could fill a significant void by offering personalized dosing and greater affordability.